AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33028254 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity measurement using pin-hole value
Number of subjects: 3400
Study 33028254 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity measurement based on presenting visual acuity value
Number of subjects: 3400
Study 33028254 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and uncorrected refractive error
Number of subjects: 3400
Study 33028254 — intervention group
Group type: EXPERIMENTAL
Intervention: Causes of visual impairment
Number of subjects: 3400
Study 35843080 — intervention group
Group type: EXPERIMENTAL
Intervention: alectinib 300 mg
Number of subjects: 207
Study 35843080 — intervention group
Group type: COMPARATOR
Intervention: crizotinib 250 mg
Number of subjects: 207
Study 34089596 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (three 3-week cycles of CAPOX, four 2-week cycles of FOLFOX or FOLFORI) followed by neoadjuvant chemoradiotherapy and surgery
Number of subjects: 364
Study 34089596 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemoradiotherapy and surgery alone
Number of subjects: 364
Study 34089596 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery
Number of subjects: 364
Study 32268000 — intervention group
Group type: EXPERIMENTAL
Intervention: RO7020531 (150 mg, multiple ascending doses every other day)
Number of subjects: 70
Study 32268000 — intervention group
Group type: EXPERIMENTAL
Intervention: RO7020531 (various doses from 40 mg to 170 mg)
Number of subjects: 70
Study 32268000 — intervention group
Group type: EXPERIMENTAL
Intervention: RO7020531 (100 mg or above)
Number of subjects: 70
Study 32268000 — intervention group
Group type: EXPERIMENTAL
Intervention: RO7020531
Number of subjects: 70
Study 32268000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 34165604 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 107
Study 34165604 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 107
Study 34081021 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive web-based system via mobile phone
Number of subjects: 22
Study 34343621 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective decision support psychoeducation
Number of subjects: 46
Study 34343621 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support communication training
Number of subjects: 46
Study 34343621 — intervention group
Group type: EXPERIMENTAL
Intervention: Ottawa Decision Guide training
Number of subjects: 46
Study 34343621 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intervention
Number of subjects: 46
Study 34459478 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth application for maternal health education
Number of subjects: 0
Study 34459478 — intervention group
Group type: COMPARATOR
Intervention: Traditional education methods (control group)
Number of subjects: 0
Study 34398184 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed messages
Number of subjects: 1316
Study 34398184 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed messages
Number of subjects: 1316
Study 34398184 — intervention group
Group type: EXPERIMENTAL
Intervention: Altruistic messages
Number of subjects: 1316
Study 34398184 — intervention group
Group type: COMPARATOR
Intervention: Non-framed information (Control)
Number of subjects: 1316
Study 33491314 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT/MICT
Number of subjects: 71
Study 33491314 — intervention group
Group type: COMPARATOR
Intervention: MICT
Number of subjects: 71
Study 34407620 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral ivabradine
Number of subjects: 60
Study 32534582 — intervention group
Group type: EXPERIMENTAL
Intervention: Throwing exercise with TheraBand
Number of subjects: 60
Study 32534582 — intervention group
Group type: COMPARATOR
Intervention: Active self‐exercise program
Number of subjects: 60
Study 35191094 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual clinic visits
Number of subjects: 875
Study 35191094 — intervention group
Group type: COMPARATOR
Intervention: Group clinic visits
Number of subjects: 875
Study 35191094 — intervention group
Group type: COMPARATOR
Intervention: Group phone visits
Number of subjects: 875
Study 34251082 — intervention group
Group type: EXPERIMENTAL
Intervention: Low inferior mesenteric artery ligation
Number of subjects: 130
Study 34251082 — intervention group
Group type: COMPARATOR
Intervention: High inferior mesenteric artery ligation
Number of subjects: 130
Study 32249995 — intervention group
Group type: EXPERIMENTAL
Intervention: Contamination mixture method
Number of subjects: 0
Study 32249995 — intervention group
Group type: EXPERIMENTAL
Intervention: Outlier-robust methods
Number of subjects: 0
Study 32249995 — intervention group
Group type: EXPERIMENTAL
Intervention: Other robust methods
Number of subjects: 0
Study 32249995 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 35129763 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully digital workflow (test group)
Number of subjects: 18
Study 35129763 — intervention group
Group type: COMPARATOR
Intervention: Conventional workflow (control group)
Number of subjects: 18
Study 35129763 — intervention group
Group type: EXPERIMENTAL
Intervention: Both workflows
Number of subjects: 18
Study 32063397 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestronidase alfa 4 mg/kg IV
Number of subjects: 12
Study 32063397 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestronidase alfa
Number of subjects: 12
Study 35617911 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT plus standardised medical care (SMC)
Number of subjects: 368
Study 35617911 — intervention group
Group type: EXPERIMENTAL
Intervention: Not receiving disability benefits, lower anxiety and/or depression scores, shorter duration, younger age at DS onset, employment, fewer symptoms, higher educational qualification, stronger belief in the diagnosis and in CBT as a 'logical' treatment
Number of subjects: 368
Study 35617911 — intervention group
Group type: COMPARATOR
Intervention: Standardised medical care (SMC) alone
Number of subjects: 368
Study 34525972 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship intervention (provider education, clinical decision aids, audit and feedback)
Number of subjects: 1682
Study 34525972 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship intervention
Number of subjects: 1682
Study 34525972 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1682
Study 32703316 — intervention group
Group type: EXPERIMENTAL
Intervention: medication plus DIT
Number of subjects: 240
Study 32703316 — intervention group
Group type: COMPARATOR
Intervention: medication plus active control psychotherapy
Number of subjects: 240
Study 32703316 — intervention group
Group type: COMPARATOR
Intervention: medication alone
Number of subjects: 240
Study 32029860 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-automated axon quantification method using freeware
Number of subjects: 1238
Study 32029860 — intervention group
Group type: COMPARATOR
Intervention: Manual counting
Number of subjects: 1238
Study 35057852 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized PEEP setting protocol driven by end-expiratory lung volume (EELV) measurement (IPERPEEP arm)
Number of subjects: 132
Study 35057852 — intervention group
Group type: COMPARATOR
Intervention: Standard PEEP setting to achieve a plateau pressure of 28-30 cmH2O (control arm, EXPRESS strategy)
Number of subjects: 132
Study 34703180 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral simvastatin (40 mg, daily) for 10 days
Number of subjects: 98
Study 34703180 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 10 days
Number of subjects: 98
Study 32926010 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg orally three times/week for 12 weeks)
Number of subjects: 48
Study 32926010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 32926010 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 48
Study 35088142 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary skin closure
Number of subjects: 120
Study 35088142 — intervention group
Group type: COMPARATOR
Intervention: Delayed primary skin closure
Number of subjects: 120
Study 33520191 — intervention group
Group type: EXPERIMENTAL
Intervention: FDI criteria
Number of subjects: 626
Study 33520191 — intervention group
Group type: COMPARATOR
Intervention: CARS criteria
Number of subjects: 626
Study 34310907 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided PCI during the index hospitalization
Number of subjects: 1545
Study 34310907 — intervention group
Group type: COMPARATOR
Intervention: Initial conservative management of non-culprit lesions
Number of subjects: 1545
Study 33228815 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radiomic signature
Number of subjects: 539
Study 33228815 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomic nomogram incorporating combined radiomic signature, age, CT T stage, and CT N stage
Number of subjects: 539
Study 33228815 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomic nomogram
Number of subjects: 539
Study 33443465 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week walking training program
Number of subjects: 11
Study 33853021 — intervention group
Group type: EXPERIMENTAL
Intervention: trauma-informed parenting intervention
Number of subjects: 414
Study 33853021 — intervention group
Group type: COMPARATOR
Intervention: foster care services as usual
Number of subjects: 414
Study 35933413 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin plus evolocumab (EE)
Number of subjects: 110
Study 35933413 — intervention group
Group type: COMPARATOR
Intervention: Empagliflozin (E)
Number of subjects: 110
Study 35829656 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab 160 mg every 4 weeks
Number of subjects: 206
Study 33268416 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer co-facilitated parental engagement educational programme
Number of subjects: 50
Study 33268416 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 50
Study 34487146 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% INU (Inulin)
Number of subjects: 30
Study 34487146 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% IMO (Isomalto-oligosaccharide)
Number of subjects: 30
Study 34487146 — intervention group
Group type: COMPARATOR
Intervention: Basal diet (Control)
Number of subjects: 30
Study 32246798 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-IL (interleave-interlink) programming paradigm
Number of subjects: 25
Study 35575988 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory Training Mask (RTM)
Number of subjects: 11
Study 35575988 — intervention group
Group type: COMPARATOR
Intervention: Control Mask
Number of subjects: 11
Study 33657293 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted 20% human albumin solution for up to 14 days or until discharge; median total infusion of 200 g (IQR, 140 to 280) per patient.
Number of subjects: 777
Study 33657293 — intervention group
Group type: COMPARATOR
Intervention: Standard care; median total infusion of 20 g (IQR, 0 to 120) per patient.
Number of subjects: 777
Study 33657293 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted albumin group
Number of subjects: 777
Study 33657293 — intervention group
Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 777
Study 33657293 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 777
Study 32075685 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary wound closure
Number of subjects: 0
Study 32075685 — intervention group
Group type: COMPARATOR
Intervention: Secondary wound healing
Number of subjects: 0
Study 34389257 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-administered HPV vaccine series completion
Number of subjects: 33
Study 34389257 — intervention group
Group type: COMPARATOR
Intervention: Control group completing the HPV vaccine series at their FQHC
Number of subjects: 33
Study 34708338 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy
Number of subjects: 202
Study 34708338 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment (SMT)
Number of subjects: 202
Study 36127081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Intervention 'SmartSafe' in addition to treatment as usual (TAU)
Number of subjects: 0
Study 36127081 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) with Ecological Momentary Assessment (EMA) monitoring
Number of subjects: 0
Study 34841676 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-exercise classes delivered via Zoom, 60-min weekly sessions by a trained exercise therapist for 3-6 months post-surgery.
Number of subjects: 12
Study 34841676 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-exercise classes
Number of subjects: 12
Study 34297072 — intervention group
Group type: EXPERIMENTAL
Intervention: 2004-2007 trials
Number of subjects: 9
Study 34297072 — intervention group
Group type: EXPERIMENTAL
Intervention: 2008-2012 trials
Number of subjects: 9
Study 34297072 — intervention group
Group type: EXPERIMENTAL
Intervention: Top 10% of sites for 2004-2007 trials
Number of subjects: 9
Study 34297072 — intervention group
Group type: EXPERIMENTAL
Intervention: Top 10% of sites for 2008-2012 trials
Number of subjects: 9
Study 34297072 — intervention group
Group type: EXPERIMENTAL
Intervention: Central IRB
Number of subjects: 9
Study 34297072 — intervention group
Group type: COMPARATOR
Intervention: Local IRB
Number of subjects: 9
Study 32379102 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% monolaurin vaginal gel
Number of subjects: 109
Study 32379102 — intervention group
Group type: COMPARATOR
Intervention: Vehicle placebo gel
Number of subjects: 109
Study 35719056 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoselective vaporization of the prostate (PVP)
Number of subjects: 71
Study 35719056 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser vaporization (DVP)
Number of subjects: 71
Study 35719056 — intervention group
Group type: EXPERIMENTAL
Intervention: Thulium laser vaporization (ThuVAP)
Number of subjects: 71
Study 33646365 — intervention group
Group type: EXPERIMENTAL
Intervention: PAINReportIt® (electronic pain reporting device)
Number of subjects: 178
Study 33646365 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 178
Study 34611113 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute psychosocial stress test
Number of subjects: 57
Study 34611113 — intervention group
Group type: COMPARATOR
Intervention: Nonstress placebo task
Number of subjects: 57
Study 34611113 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipatory cognitive stress appraisal
Number of subjects: 57
Study 34611113 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH increases
Number of subjects: 57
Study 34169797 — intervention group
Group type: EXPERIMENTAL
Intervention: Vena cava filter
Number of subjects: 240
Study 35661029 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality combined with robot-assisted gait training with 15% weight loss (Group A)
Number of subjects: 60
Study 35661029 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality combined with robot-assisted gait training with 30% weight loss (Group B)
Number of subjects: 60
Study 35661029 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality combined with robot-assisted gait training with 45% weight loss (Group C)
Number of subjects: 60
Study 35661029 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (Control group)
Number of subjects: 60
Study 34167426 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory hysteroscopy (AH)
Number of subjects: 329
Study 34167426 — intervention group
Group type: COMPARATOR
Intervention: Hysteroscopy under general anaesthesia (GA)
Number of subjects: 329
Study 32114892 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum YKL-40
Number of subjects: 2200
Study 32114892 — intervention group
Group type: COMPARATOR
Intervention: Standard predictors
Number of subjects: 2200
Study 32114892 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum YKL-40 added as a predictor
Number of subjects: 2200
Study 36042436 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate loading according to the Enhanced Recovery After Surgery (ERAS) protocol
Number of subjects: 66
Study 36042436 — intervention group
Group type: COMPARATOR
Intervention: Control group (fasting from midnight)
Number of subjects: 66
Study 34274907 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 56
Study 34274907 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% sodium chloride)
Number of subjects: 56
Study 35807797 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with almonds (MDSA)
Number of subjects: 38
Study 35807797 — intervention group
Group type: COMPARATOR
Intervention: Usual dietary pattern (Control)
Number of subjects: 38
Study 32332635 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60
Study 32332635 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment measures
Number of subjects: 60
Study 615988346 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (100 mg/mL)
Number of subjects: 0
Study 615988346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36254732 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic interval (CI) - surgery within 8 weeks after CRT
Number of subjects: 350
Study 36254732 — intervention group
Group type: COMPARATOR
Intervention: Long interval (LI) - surgery after more than 8 weeks after CRT
Number of subjects: 350
Study 35714163 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacticaseibacillus rhamnosus HA‐114 supplementation
Number of subjects: 152
Study 35714163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 33549260 — intervention group
Group type: EXPERIMENTAL
Intervention: Published RCTs (638 trials, 93.3%)
Number of subjects: 434610
Study 33549260 — intervention group
Group type: COMPARATOR
Intervention: Unpublished RCTs (46 trials, 6.7%)
Number of subjects: 434610
Study 33549260 — intervention group
Group type: COMPARATOR
Intervention: All unpublished trials
Number of subjects: 434610
Study 33279855 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT + RT70
Number of subjects: 600
Study 33279855 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT + DERT76
Number of subjects: 600
Study 33279855 — intervention group
Group type: COMPARATOR
Intervention: DERT76
Number of subjects: 600
Study 33279855 — intervention group
Group type: EXPERIMENTAL
Intervention: RT 70 Gy
Number of subjects: 600
Study 33279855 — intervention group
Group type: COMPARATOR
Intervention: RT 76 Gy
Number of subjects: 600
Study 32448796 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised decision-support tool to assist with antidepressant choices
Number of subjects: 0
Study 32448796 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 0
Study 32380566 — intervention group
Group type: EXPERIMENTAL
Intervention: Retosiban
Number of subjects: 120
Study 32380566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 32380566 — intervention group
Group type: COMPARATOR
Intervention: Atosiban
Number of subjects: 120
Study 33075789 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tramadol (100 mg in 100 mL normal saline over 10 min)
Number of subjects: 100
Study 33075789 — intervention group
Group type: COMPARATOR
Intervention: Intravenous paracetamol (1 g in 100 mL normal saline over 10 min)
Number of subjects: 100
Study 36375187 — intervention group
Group type: EXPERIMENTAL
Intervention: High thoracic-ESPB
Number of subjects: 96
Study 36375187 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block (SSNB)
Number of subjects: 96
Study 36375187 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study 33728717 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg
Number of subjects: 849
Study 33728717 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg
Number of subjects: 849
Study 33060498 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure applied to HE‐7 acupuncture points for 10 minutes before surgery
Number of subjects: 82
Study 33060498 — intervention group
Group type: COMPARATOR
Intervention: Control group subjected to hospital protocol
Number of subjects: 82
Study 35409815 — intervention group
Group type: EXPERIMENTAL
Intervention: Centre-based exercise-training program (eight weeks, three times per week)
Number of subjects: 40
Study 35409815 — intervention group
Group type: COMPARATOR
Intervention: Maintain daily habits
Number of subjects: 40
Study 33529168 — intervention group
Group type: EXPERIMENTAL
Intervention: High residual C-peptide concentration (>0.2 nmol/L)
Number of subjects: 944
Study 33529168 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate residual C-peptide concentration (>0.03 to ≤0.2 nmol/L)
Number of subjects: 944
Study 33529168 — intervention group
Group type: EXPERIMENTAL
Intervention: Low residual C-peptide concentration (≥ 0.003 to ≤0.03 nmol/L)
Number of subjects: 944
Study 33529168 — intervention group
Group type: EXPERIMENTAL
Intervention: No residual C-peptide concentration (<0.003 nmol/L)
Number of subjects: 944
Study 33529168 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders (with residual C-peptide)
Number of subjects: 944
Study 33529168 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresponders (no residual C-peptide)
Number of subjects: 944
Study 33457410 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of modern family planning methods
Number of subjects: 577
Study 33457410 — intervention group
Group type: EXPERIMENTAL
Intervention: Husband approval
Number of subjects: 577
Study 33457410 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple's discussion
Number of subjects: 577
Study 33457410 — intervention group
Group type: EXPERIMENTAL
Intervention: Male involvement in decisions about family planning
Number of subjects: 577
Study 33457410 — intervention group
Group type: EXPERIMENTAL
Intervention: Desire for additional child
Number of subjects: 577
Study 33457410 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous use of contraception
Number of subjects: 577
Study 35486088 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol tablets (test product)
Number of subjects: 48